Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
Adam Zayac(Rutgers, The State University of New Jersey), Matthew A. Lunning(University of Nebraska Medical Center), Maryam Sarraf Yazdy(Georgetown University), Bradley M. Haverkos(University of Colorado Denver), Lori A. Leslie(Hackensack University Medical Center), Gabriella Magarelli(Hackensack University Medical Center), Madelyn Burkart(Atrium Health Wake Forest Baptist), Kirsten M Boughan(Cleveland Clinic), Christopher R. D’Angelo(Susan Thompson Buffett Foundation), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Kevin A. David(Rutgers, The State University of New Jersey), Catherine Diefenbach(NYU Langone Health), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Emma Rabinovich(University of Illinois Chicago), Sarah Stettner(University of Illinois Chicago), Vaishalee P. Kenkre(University of Wisconsin–Madison), Michael C. Churnetski(Emory University), Gaurav Varma(NYU Langone Health), Peter Martin(Northwestern University), Max J. Gordon(Oregon Health & Science University), Allandria Straker-Edwards(Fox Chase Cancer Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Amandeep Godara(University of Utah), Kristie A. Blum(Emory University), Catherine Wei(Rutgers, The State University of New Jersey), Andreas K. Klein(Tufts Medical Center), Andrew M. Evens(Rutgers, The State University of New Jersey), Asaad Trabolsi(University of Miami), Yusra F. Shao(Wayne State University), Alexey V. Danilov(City of Hope), Malvi Savani(University of Minnesota), Amy Sperling(Fred Hutch Cancer Center), Victor M. Orellana‐Noia(University of Virginia), Stephanie Berg(Loyola University Medical Center), Nadia Khan(Fox Chase Cancer Center), Seth Maliske(University of Iowa), Seema Naik(CHRISTUS Transplant Institute), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Nishitha Reddy(Vanderbilt University), Ayushi Chauhan(Georgetown University), Narendranath Epperla(University of Utah), Stephen D. Smith(Seattle Cancer Care Alliance), Daulath Singh(Loyola University Medical Center), Umar Farooq(Wake Forest University), Seohyun Kim(Rush University Medical Center), Ryan Vaca(Penn State Milton S. Hershey Medical Center), Reem Karmali(Northwestern University), Yun Kyong Choi(New York University), Manali Kamdar(University of Colorado Cancer Center)
Cited by 44
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k